Work

Valaciclovir for herpesvirus treatment and prevention in Janus kinase inhibitor‐treated patients: an Australian experience and registry call

Year: 2026

Type: article

Abstract: The data that supports the findings of this study are available in the supplementary material of this article. Supplementary Table S1. High vs Standard/Other Dosing of Janus kinase Inhibitors. Derived from the “Monthly Index of Medical Specialties”, accessed November 2024. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Source: Internal Medicine Journal

DOI: 10.1111/imj.70374

Authors: Adele Batrouney, Zoe Kantanis, Rohan A Elliott, Elise Mitri, Karen Urbancic, Stephen Cheung, Olivia C Smibert, Lionel Schachna, Satwik Motaganahalli, Jason A Trubiano, Gemma Reynolds

Institutions: Austin Hospital, Austin Health, Monash University, The University of Melbourne, Peter Doherty Institute, Peter MacCallum Cancer Centre

Language: English

Topic: Herpesvirus Infections and Treatments

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7128910744

FWCI:

Cites: 8

Cited by:

Related to: